Lactobacillus plantarum P8

Lactobacillus plantarum P8 is a probiotic strain that produces gamma-aminobutyric acid (GABA) and short-chain fatty acids to modulate the gut-brain axis. This strain clinically demonstrates stress reduction, anxiety relief, and cognitive enhancement through neuroinflammation reduction.

Origin & History

Lactobacillus plantarum P8 is a specific probiotic strain isolated from traditionally fermented sour milk samples collected from herdsmen in Wulatezhongqi grassland, Inner Mongolia, China. It was selected from 347 Lactobacillus strains for its superior tolerance to gastric acid, intestinal fluid, and bile salts. The strain is cultured and incorporated into products like dairy, supplements, and pet foods, often in powdered or microencapsulated forms produced under ISO9001 and HALAL standards.

Historical & Cultural Context

L. plantarum P8 originates from traditionally fermented sour milk used by herdsmen families on the Wulat Zhongqi grassland in Inner Mongolia, China. While the strain itself was isolated for modern probiotic applications, no specific historical duration or traditional medicinal uses are documented. The strain was scientifically screened from natural samples rather than having established traditional therapeutic use.

Health Benefits

• Reduces stress and anxiety - RCT showed significant reductions in stress (P=0.048) and anxiety (P=0.031) after 4 weeks (strong evidence)
• Improves memory and cognitive function - Clinical trial demonstrated enhanced cognition via DASS-42 scales (moderate evidence)
• Enhances gut microbiota balance - Human trials showed increased beneficial bacteria and short-chain fatty acids (moderate evidence)
• Boosts intestinal immunity - Studies found elevated secretory IgA and improved gut barrier integrity (moderate evidence)
• Inhibits harmful pathogens - Demonstrated activity against E. coli O157:H7 and other gastrointestinal pathogens (preliminary evidence from animal studies)

How It Works

Lactobacillus plantarum P8 produces GABA and short-chain fatty acids like butyrate that cross the blood-brain barrier and bind to GABA receptors in the central nervous system. The strain reduces pro-inflammatory cytokines IL-6 and TNF-α while increasing anti-inflammatory IL-10 production. It also enhances tryptophan metabolism along the kynurenine pathway, increasing serotonin synthesis for mood regulation.

Scientific Research

A randomized, double-blind, placebo-controlled trial (n=120 stressed adults, PMID: 30266270) tested L. plantarum P8 at 10^10 CFU/day for 4 weeks, showing significant reductions in stress and anxiety while improving cognition. Two additional human trials demonstrated improvements in gastrointestinal health through enhanced beneficial microbiota and immune markers. Animal studies support immune benefits, though human RCTs remain limited to stress/anxiety and gut health outcomes.

Clinical Summary

A randomized controlled trial with 103 adults showed significant stress reduction (P=0.048) and anxiety reduction (P=0.031) after 4 weeks of supplementation. Cognitive improvements were measured using DASS-42 depression, anxiety and stress scales, demonstrating moderate evidence for memory enhancement. The studies used dosages of 10^9 CFU daily, though sample sizes remain relatively small and longer-term studies are needed to confirm sustained benefits.

Nutritional Profile

Lactobacillus plantarum P8 is a live bacterial strain, not a traditional macronutrient source. As a probiotic ingredient, its nutritional profile is characterized by bioactive components rather than conventional macro/micronutrients. Typical viable cell concentration in commercial preparations: 1×10⁹ to 1×10¹⁰ CFU per serving dose. Bioactive compounds include: (1) Exopolysaccharides (EPS) - produced during fermentation, contributing to gut mucosa adhesion and immune modulation, estimated 50–200 mg/g dry cell weight depending on growth medium; (2) Short-chain fatty acid (SCFA) precursors - the strain facilitates production of acetate, propionate, and butyrate in the colon, with human trials showing measurable increases in fecal SCFA concentrations post-supplementation; (3) Bacteriocins and antimicrobial peptides - strain produces plantaricin-class peptides that inhibit pathogenic bacteria, approximate molecular weight 3–10 kDa; (4) Cell wall components including lipoteichoic acids and peptidoglycans that interact with toll-like receptors (TLR-2), contributing to immunomodulatory effects; (5) B-vitamins (folate/B9 and riboflavin/B2) synthesized during metabolism, trace quantities estimated at 0.1–0.5 µg/10⁹ CFU; (6) Proteins constituting approximately 50–60% of dry cell mass, though not bioavailable as dietary protein in conventional sense. Bioavailability note: Strain demonstrates moderate-to-high gastric acid and bile salt tolerance (survival rate ~60–75% through simulated GI transit), enhancing colonization potential compared to less robust probiotic strains. Carrier matrix (dairy, capsule, or fermented food base) significantly affects bioavailability and CFU viability at point of consumption.

Preparation & Dosage

Clinically studied dose: 10^10 CFU/day (10 billion CFU), delivered in 2g powder sachets for 4-12 weeks. Available forms include powder sachets and microencapsulated preparations. No standardized extract forms have been studied. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Other probiotic strains, Prebiotics (FOS/GOS), L-theanine, Magnesium, B-complex vitamins

Safety & Interactions

Lactobacillus plantarum P8 is generally well-tolerated with minimal reported side effects in clinical trials. Mild gastrointestinal symptoms like bloating or gas may occur during initial supplementation as gut microbiota adjusts. No significant drug interactions have been documented, though individuals on immunosuppressive medications should consult healthcare providers. Safety during pregnancy and breastfeeding has not been established through clinical research.